Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) is a phase 3 interventional study registered as NCT06109779 by AstraZeneca, with 760 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2029-01-02. Interventions recorded: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin and S-1 [Tegafur/Oteracil/gimeracil].
Similar pages
not linked directly; found by shared links- TrialA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Shares Gemcitabine + cisplatin, Rilvegostomig, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.